Hazard ratios for prostate cancer in the IMPACT study, (Cox regression analyses) and for breast cancer in the RMH study, (weighted retrospective Cox regression analyses), by BRCA1/2 mutation status. This evidence concerns the gene BRCA1 and prostate carcinoma.